Full Press Release Details
Biotech Holds Annual General Meeting
September 18 -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of
vaccines in China, today announced that its Annual General Meeting originally
scheduled for September 4, 2008 was held two weeks later, on September 18,
the September 18, Annual General Meeting, held at Sinovac's headquarters located
at No. 39, Shangdi Xi Rd., Haidian District, Beijing, PRC, the Company's 2007
Annual Report was reviewed, and the appointment of Ernst & Young as
Sinovac's registered public accountants was approved.
Biotech Ltd. is a China-based biopharmaceutical company that focuses on the
research, development, manufacture and commercialization of vaccines that
protect against human infectious diseases. Sinovac's vaccines include Healive
(hepatitis A), Bilive (combined hepatitis A and B), Anflu (influenza) and
Panflu(TM)(H5N1). Sinovac is currently developing Universal Pandemic Influenza
vaccine and Japanese encephalitis vaccine. Additional information about Sinovac
is available on its website, http://www.sinovac.com . To be added to our
distribution list, please email: info@sinovac.com.
information, please contact:
Tel: +86-10-8289-0088
Fax: +86-10-6296-6910
Carrington/Janine McCargo
Tel: +1-646-536-7017/7033